Table 1 Topical chemotherapy for ocular surface squamous neoplasia (OSSN)
From: Update on pharmacotherapy for ocular surface squamous neoplasia
Most common OSSN treatment options | Formulation | Dosage | Side effects |
|---|---|---|---|
IFN-a2b | Topical: 1 MIU/ml (Alternative: 2–3 MIU/ml), Subconjunctival injections: 3 million IU/0.5 ml (Alternative: 10 MIU/month) | Topical: 4 times a day drops continuously, Subconjunctival: Weekly injections until resolution (typically 4–5 weeks) | Minimal side effects for drops, flu-like malaise with injections |
5-FU | Topical: 1% drops | 4 times a day for 1 week with 3 weeks off (Alternative: 4 times daily for 2 days to 4 weeks) | Mild pain, lid edema, epitheliopathy |
MMC | Topical: 0.02–0.04% drops | 4 times a day for 1 week followed by 2–3 weeks off until the eye is quiet. Usually 3–4 cycles until resolution (Alternative: 7–14 day cycles) | Pain, keratopathy, punctal stenosis, LSCD |